Business
Amarantus to Commence Trading on the OTCQX Marketplace Under Existing Ticker Symbol AMBS
Amarantus to Commence Trading on the OTCQX Marketplace Under Existing Ticker Symbol AMBS.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\nSAN FRANCISCO and GENEVA, July 13, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has received approval to commence trading on the OTCQX® Best Marketplace (OTCQX) at market open today, July 13, 2015, under its existing ticker symbol, \"AMBS.\"\n\n\t\"We are very pleased to have achieved OTC Markets Group's requirements for its premier securities marketplace,\" said Gerald E. Commissiong, President and Chief Executive Officer of Amarantus. \"Trading on the OTCQX is another step toward our goal of a near-term up-listing to a national stock exchange, and will improve the Company's ability to attract institutional investors from both inside and outside the United States. This latest corporate milestone should provide additional visibility within the investment community enabling us to build awareness more broadly and expand the current shareholder base in order to drive shareholder value.\"\n\n\tInvestors may find current financial disclosure and real-time quotes for Amarantus on www.otcmarkets.com.\n\n\tAbout Amarantus BioScience Holdings, Inc.\n\n\tAmarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. AMBS' Therapeutics division has development rights to eltoprazine, a Phase 2b small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS' Diagnostics division owns the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual proper...